医渡科技(02158)10月17日斥资101.31万港元回购18.12万股

智通财经网· 2025-10-17 11:12
智通财经APP讯,医渡科技(02158)发布公告,于2025年10月17日,该公司斥资101.31万港元回购18.12万 股股份,每股回购价格为5.56-5.65港元。 ...
创联控股(02371):路行辞任执行董事兼董事会主席
智通财经网· 2025-10-17 11:12
Core Viewpoint - Chuanglian Holdings (02371) announced the resignation of Mr. Lu Xing as Executive Director and Chairman of the Board, effective from October 17, 2025, due to his desire to focus more on personal business development [1] Company Summary - Chuanglian Holdings is undergoing a leadership change with the resignation of its Executive Director and Chairman, which may impact its strategic direction and operational focus [1]
海昌海洋公园(02255):曲乃杰调任为非执行董事
智通财经网· 2025-10-17 11:12
于完成后,董事会宣布,曲乃杰已辞任执行董事、本公司行政总裁及董事会主席,李珂晖已辞任执行董 事,以及王旭光、 Go Toutou及袁兵已辞任非执行董事,以处理其个人及╱或业务事务。上述辞任均已 于本公布日期生效。 辞任后,曲乃杰、王旭光及袁兵分别不再担任本公司提名委员会主席、薪酬委员会成员以及风险管理及 企业管治委员会主席。 自2025年10月17日起,曲乃杰将由执行董事调任为非执行董事。 智通财经APP讯,海昌海洋公园(02255)发布公告,董事会欣然宣布,认购协议项下的所有先决条件均已 获达成,且认购事项已根据认购协议的条款及条件于2025年10月17日完成。于完成时,本公司已根据于 股东特别大会上向独立股东寻求的特别授权,按认购价每股认购股份0.45港元向认购人正式配发及发行 51亿股认购股份。认购股份占紧接完成前本公司现有已发行股本约 62.85%,以及占紧随完成后本公司 已发行股本约38.60%。 董事会进一步宣布,(i)曲乃杰亦已根据上市规则第3.05条辞任本公司授权代表,自2025年10月17日起生 效,及(ii)在其辞任后,詹新伟已获委任取代曲乃杰作为本公司的其中一名授权代表。 董事会欣然宣布 ...
医渡科技(02158.HK)10月17日耗资101.3万港元回购18.1万股

Ge Long Hui· 2025-10-17 11:11
格隆汇10月17日丨医渡科技(02158.HK)公告,10月17日耗资101.3万港元回购18.1万股,每股回购价5.56- 5.65港元。 ...
到手的“肉签”飞了?海西新药是延迟上市还是被迫中止?
Zhi Tong Cai Jing· 2025-10-17 11:10
Core Viewpoint - The recent postponement of the IPO for Haixi New Drug highlights ongoing challenges in the Hong Kong stock market, particularly regarding the identification and verification of investors, which has led to concerns about potential irregularities in subscription applications [4][5][9]. Group 1: IPO Details - Haixi New Drug's IPO was initially scheduled for October 17, following a successful subscription period from October 9 to October 14, which attracted HKD 309.4 billion in margin financing, resulting in an oversubscription of 3,113 times [4]. - The company planned to issue 11.5 million shares, with approximately 10% allocated for public offering in Hong Kong and 90% for international placement, at a price range of HKD 69.88 to HKD 86.40 per share [4][9]. - The postponement was announced after the stock experienced a 25% increase in the dark market, raising questions about the reasons behind the delay, which were clarified to be related to the need for additional time to finalize the allocation results [4][8]. Group 2: Market Context - The Hong Kong IPO market has seen a significant increase in activity, with 66 new stocks listed in the first three quarters of the year, representing a 46.7% year-on-year growth and total fundraising of HKD 182.4 billion, a 228.1% increase [7]. - The pharmaceutical sector has been particularly strong, with seven out of the top ten performing new stocks in the first nine months being healthcare-related, reflecting a robust demand for innovative drugs [7]. Group 3: Company Profile - Haixi New Drug operates on a hybrid model focusing on both generic and innovative drugs, with a strong emphasis on first-generic, difficult-to-generate, and high-generic drug development [9]. - The company has a pipeline that includes one Phase II clinical project and three preclinical projects targeting oncology, ophthalmology, and respiratory diseases [9]. - Financially, Haixi New Drug reported revenues of approximately HKD 2.12 million, HKD 3.17 million, HKD 4.67 million, and HKD 2.49 million over the past four years, with a compound annual growth rate of 48.4% [9]. Group 4: Valuation Insights - The IPO valuation for Haixi New Drug is approximately 41 times PE (TTM), which is lower than the average PE of 58 times for similar A-share generic drug companies, suggesting potential for appreciation [10]. - The PS valuation is around 13 times, indicating a favorable comparison to peer companies in the market [10].
北水成交净买入63.03亿 北水继续抛售中芯华虹 全天抢筹美团超11亿港元
Zhi Tong Cai Jing· 2025-10-17 11:10
Core Insights - The Hong Kong stock market saw a net inflow of 63.03 billion HKD from northbound trading, with the Shanghai Stock Connect contributing 56.56 billion HKD and the Shenzhen Stock Connect contributing 6.47 billion HKD [1] Group 1: Stock Performance - The most bought stocks included Meituan-W (03690), Tracker Fund of Hong Kong (02800), and CNOOC (00883) [1] - The most sold stocks included Alibaba-W (09988), SMIC (00981), and Hua Hong Semiconductor (01347) [1] Group 2: Detailed Stock Transactions - Alibaba-W (09988) had a buy amount of 36.49 billion HKD and a sell amount of 47.61 billion HKD, resulting in a net outflow of 11.12 billion HKD [2] - SMIC (00981) saw a buy amount of 28.06 billion HKD and a sell amount of 26.47 billion HKD, resulting in a net inflow of 1.59 billion HKD [2] - Meituan-W (03690) had a buy amount of 12.26 billion HKD and a sell amount of 5.78 billion HKD, resulting in a net inflow of 6.48 billion HKD [2] Group 3: Market Trends and News - Meituan announced an upgrade to its "Prosperity Plan" for restaurant merchants, allocating an additional 2.8 billion HKD to support profit retention and healthy development [6] - CNOOC received a net inflow of 5.39 billion HKD, with analysts suggesting that stable oil prices and high dividends could enhance its valuation [6] - Alibaba's significant net outflow of 21.53 billion HKD comes amid the launch of its Double 11 promotional campaign, with substantial investments in marketing [8]
新享时代:股份合并将于10月20日生效
Zhi Tong Cai Jing· 2025-10-17 11:10
新享时代(08519)公布,股份合并的所有条件均已达成,且股份合并将于2025年10月20日(星期一)生效。 合并股份将于2025年10月20日(星期一)上午九时正于联交所开始买卖。 ...
海螺环保:李亮贤辞任联席公司秘书
Zhi Tong Cai Jing· 2025-10-17 11:10
公司另一名联席公司秘书李亮贤先生已辞任本公司联席公司秘书,自2025年10月17日起生效。 海螺环保(00587)发布公告,联交所已确认廖丹女士已符合上市规则第3.28条所规定担任公司秘书的资 格。因此,廖丹女士将独立担任公司秘书,自2025年10月17日生效。 ...
新享时代(08519):股份合并将于10月20日生效
Zhi Tong Cai Jing· 2025-10-17 11:09
(原标题:新享时代(08519):股份合并将于10月20日生效) 智通财经APP讯,新享时代(08519)公布,股份合并的所有条件均已达成,且股份合并将于2025年10月20 日(星期一)生效。合并股份将于2025年10月20日(星期一)上午九时正于联交所开始买卖。 ...
海螺环保(00587):李亮贤辞任联席公司秘书
Zhi Tong Cai Jing· 2025-10-17 11:09
(原标题:海螺环保(00587):李亮贤辞任联席公司秘书) 智通财经APP讯,海螺环保(00587)发布公告,联交所已确认廖丹女士已符合上市规则第3.28条所规定担 任公司秘书的资格。因此,廖丹女士将独立担任公司秘书,自2025年10月17日生效。 公司另一名联席公司秘书李亮贤先生已辞任本公司联席公司秘书,自2025年10月17日起生效。 ...